Treats relapsing forms of multiple sclerosis (MS). ANDA 206936, held by Mylan. Glatiramer Acetate.
As of Nov 16, 2026, ANDA 206936 (Glatiramer Acetate), held by Mylan, was first approved by FDA on Oct 3, 2017, with 9 approved supplements and 0 published complete response letters.
Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 3, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Glatiramer Acetate40MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
| Feb 15, 2024 | Supplement 19Labeling · Standard review | Approved | None posted |
| Feb 15, 2024 | Supplement 20Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Supplement 16Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 3, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters